A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Recruiting · Phase 1, Phase 2 · NCT05648214
Conditions: Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
At a glance
- Research payments reported, 2025
- $641,806
- U.S. investigators named
- 7
- Sites paid
- 6
- Planned or actual enrollment
- 172
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- ALN-PNP (drug), Placebo (PB) (drug)
- Dates
- Started 2022-12-27; completion 2027-08-10
- Results posted
- Not yet
This study is researching an experimental drug called ALN-PNP (called "study drug"). This is a first in human study. The study drug is not approved by any public health agency such as the United States Food and Drug Administration (FDA) for any kind of treatment. This study consists of 3 parts. Part A is focused on healthy participants. Parts B and C of the study are focused on participants who are known to have MASLD and a specific variant of the PNPLA3 gene. The aim of the study is to see how safe, tolerable and effective the study drug is. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug (Parts A, B and C) * …
From ClinicalTrials.gov, last updated 2026-04-16. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $641,806 in research payments for this study in 2025 (156 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- David Guzman, M.D. Internal Medicine · Los Angeles, CA
- Jeffrey London, MD Internal Medicine · West Hills, CA
- Jeffrey S. Overcash, MD Emergency Medicine · Chula Vista, CA
- Eugenio Angueira-serrano, MD Endocrinology & Diabetes · Miami, FL
- Angel O. Vento, MD Gastroenterology · Miami, FL
- Gary M. Reiss, MD Gastroenterology · Marrero, LA
- Francisco J. Velazquez, MD Internal Medicine · Bellaire, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Genoma Research Group Inc $309,664
- Velocity Clinical Research Inc $153,861
- Pioneer Research Solutions Inc $64,704
- Med Research of Florida LLC $48,381
- San Fernando Valley Health Institute LLC $47,171
- Tandem Intermediate LLC $18,026
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.